# Praxis Precision Medicines (PRAX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/PRAX
## Company Profile
- Ticker: PRAX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: CNS
## Stock Data
- Close: 243.34 USD
- Market cap: 7194953993.919999 USD
- Last updated: 2026-10-13
## Business Overview
### Precision Neuroscience
Praxis Precision Medicines develops therapies for genetically and physiologically defined disorders of neuronal excitation. Its pipeline spans movement disorders and developmental epilepsies.
### Ulixacaltamide
Ulixacaltamide is a small-molecule T-type calcium-channel modulator under FDA review for essential tremor.
### Relutrigine
Relutrigine is under Priority Review for SCN2A- and SCN8A-related developmental and epileptic encephalopathies.
### Vormatrigine
Vormatrigine is an oral precision medicine being evaluated in the POWER1 study for focal-onset seizures.
### Elsunersen
Elsunersen is an antisense oligonucleotide targeting the underlying biology of SCN2A-related developmental and epileptic encephalopathy.
## Why The Stock Is Moving

As of Oct 13, 2026, PRAX closed down 3.20% at $243.34. No new same-company headline was identified in the current news window.

## Future Catalysts

- Topline POWER1 results for vormatrigine in the second quarter of 2026.
- PDUFA target date for relutrigine on September 27, 2026.
- Topline EMERALD results for relutrigine in broad developmental and epileptic encephalopathies in the fourth quarter of 2026.
- PDUFA target date for ulixacaltamide on January 29, 2027.

## Recent News
- 2026-10-02 20:01 EST — [Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing--de4d1df8) — Source: Praxis Precision Medicines
- 2026-08-06 12:00 EST — [Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-second-quarter--02c621cf) — Source: Praxis Precision Medicines
- 2026-07-30 20:01 EST — [Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026](https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-to-report-second-quarter-2026-financial-results-on-th-16ae1983) — Source: Praxis Precision Medicines
- 2026-07-07 12:00 EST — [Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor](https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-and-remagine-labs-announce-strategic-collaboration-to-0ffd9b54) — Source: Praxis Precision Medicines
- 2026-06-29 20:30 EST — [Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies](https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-announces-extension-period-for-relutrigine-for-treatm-f28fc662) — Source: Praxis Precision Medicines